 |
|
|
| |
Changes in Inflammatory Biomarkers and Baseline Variables After Switching to
Dolutegravir/Lamivudine (DTG/3TC) in 2 Randomized Clinical Trials of Virologically
Suppressed Adults: 48-Week Pooled Analysis
|
| |
| |
AIDS 2022 July 29-Aug 1 Montreal
Josep M. Llibre,1 Stefan Scholten,2 Olayemi Osiyemi,3 Richard Grove,4 James Oyee,4 Ruolan Wang,5 Brian Wynne,5 Cynthia Donovan,5 Bryn Jones,6 Chinyere Okoli,6
Michelle Kisare,7 Mounir Ait-Khaled6
1Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; 2Praxis Hohenstaufenring, Cologne, Germany; 3Triple O Research Institute PA, West Palm Beach, FL, USA; 4GSK, Brentford, UK; 5ViiV Healthcare,
Durham, NC, USA; 6ViiV Healthcare, Brentford, UK; 7GSK, Nairobi, Kenya
|
| |
|
|
|
|
|
